How is Blincyto taken / administered?
Blincyto (blinatumomab) is a cancer treatment given as a continuous IV infusion over 28 days. You then have a break with no treatment. This is called a treatment cycle which includes the treatment days and treatment-free days.
How many treatment cycles you have will depend on which type of acute lymphoblastic leukemia (ALL) you are treating.
MRD-positive B-cell Precursor ALL:
- One induction cycle (28 days treatment, 14 days no treatment)
- Up to three additional cycles for consolidation (28 days treatment, 14 days no treatment)
Relapsed or Refractory B-cell Precursor ALL:
- Two induction cycles (28 days treatment, 14 days no treatment)
- Three additional cycles for consolidation (28 days treatment, 14 days no treatment)
- Up to four additional cycles of continued therapy (28 days treatment, 56 days no treatment)
Cycles may be interrupted due to adverse reactions.
For more information on dosage and administration of Blincyto click here: Dosage and administration of Blincyto
References
- Blincyto Professional Information: Accessed July 10, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125557s023s026lbl.pdf
- Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date: Accessed 24 February 2021 : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173178/
Read next
What are monoclonal antibodies?
Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading
How much does Blincyto (blinatumomab) cost?
The cost of a Blincyto (blinatumomab) vial is approximately $5,427 per 35 microgram (mcg) single-dose vial for injection. The overall cost for your therapy will also depend upon the length of treatment. Most people do not pay out-of-pocket for the full price of Blincyto. Continue reading
Is Blincyto a type of immunotherapy?
Blincyto is a type of immunotherapy called a bispecific monoclonal antibody. This means that it binds to two different molecules at the same time – a protein called CD19 which exists on the surface of B-cell leukemia or lymphoma cells and a protein called CD3 which is expressed on T cells (a specific type of immune system cell). Blincyto may also be called a targeted treatment. Continue reading
Related medical questions
- Is Blincyto (blinatumomab) chemotherapy?
- How does Besponsa work to treat Acute Lymphoblastic Leukemia (ALL)?
- What is the lifetime or cumulative dose for Adriamycin?
- What to avoid when taking Gleevec?
- How much does Tecartus cost?
- Gleevec vs Sprycel vs Tasigna - how do they compare?
- How long does it take Sprycel (dasatinib) to start working?
- Is there a generic for Gleevec?
- Is Sprycel a chemotherapy drug?
- How does Gleevec (imatinib) work?
- What is the cost of Kymriah?
- Is Tecartus a one-time treatment?
- Is Tasigna a form of chemotherapy?
- What is the survival rate of Kymriah?
- Can I take Gleevec while pregnant?
- How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?
- How is Kymriah administered?
- What type of drug is Kymriah (tisagenlecleucel)?
Drug information
Related support groups
- Blincyto (5 questions, 4 members)
- Blinatumomab (3 questions, 4 members)
- Acute Lymphoblastic Leukemia (22 questions, 15 members)